What is JenaValve?
Founded in 1995 and headquartered in Irvine, California, JenaValve specializes in the design and manufacturing of advanced medical devices, specifically focusing on native aortic valve leaflets. The company operates at the intersection of biotechnology and mechanical engineering, addressing complex cardiovascular conditions through innovative, minimally invasive solutions. By prioritizing high-precision medical technology, JenaValve has established a robust market position, attracting significant interest from institutional investors and private equity firms that specialize in life sciences and healthcare innovation. Its long-standing commitment to clinical excellence and patient outcomes has made it a focal point for strategic growth within the global medtech landscape.
How much funding has JenaValve raised?
JenaValve has raised a total of $283.3M across 8 funding rounds:
Series A
$14M
Private Equity
$13.5M
Series B
$19M
Private Equity
$10M
Private Equity
$9.4M
Debt
$4.9M
Other Financing Round
$50M
Series C
$162.5M
Series A (2007): $14M with participation from Edmond de Rothschild Investment Partners and Atlas Venture
Private Equity (2010): $13.5M, investors not publicly disclosed
Series B (2010): $19M supported by Sunstone Capital, VI Partners AG, and Gimv
Private Equity (2016): $10M, investors not publicly disclosed
Private Equity (2017): $9.4M, investors not publicly disclosed
Debt (2018): $4.9M, investors not publicly disclosed
Other Financing Round (2020): $50M led by RMM Solutions Inc, Andera Partners, VI Partners AG, NeoMed Management, Bain Capital LP, Valiance Asset Management Limited, Gimv, and Legend Capital Co. Ltd
Series C (2022): $162.5M supported by Bain Capital Life Sciences, Gimv, Andera Partners, and Valiance Advisors
Key Investors in JenaValve
Gimv
Gimv is a European investment company that specializes in partnering with mid-market businesses to foster sustainable growth across five strategic sectors, including Healthcare and Life Sciences.
Andera Partners
Andera Partners is a major player in private company investments, managing over 3.5 billion in assets with a dedicated life sciences team focused on biotech and medtech innovation.
Sunstone Capital
Sunstone Life Science Ventures is an independent European venture capital firm focused on enabling and empowering life science therapeutics innovations to improve patient outcomes.
What's next for JenaValve?
With the successful closure of its recent financing round, JenaValve is well-positioned to transition into a phase of aggressive commercial expansion and product development. The strategic focus will likely center on scaling manufacturing capabilities to meet global demand while simultaneously pursuing further clinical validation for its core valve technologies. As the company moves forward, the integration of these funds will be pivotal in navigating regulatory landscapes and expanding its footprint in international markets. Investors remain focused on the company's ability to translate its technical expertise into sustained market share, ensuring that JenaValve remains at the forefront of cardiovascular innovation in the coming years.
See full JenaValve company page
